OpenAlex
PricingAboutJobs
Log inGet started
Work

The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.

PubMed

Year: 2008
Type: article
Source: PubMed
Authors: Joann P Palma, Luis E Rodriguez, Velitchka D Bontcheva-Diaz, Jennifer J Bouska, Gail Bukofzer, Milagros Colon-Lopez, Ran Guan, Kenneth Jarvis, Eric F Johnson, Vered Klinghofer, Xuesong Liu, Amanda Olson, Mary J Saltarelli, Yan Shi, Jason A Stavropoulos, Gui-Dong Zhu, Thomas D Penning, Yan Luo, Vincent L Giranda, Saul H Rosenberg, David J Frost, Cherrie K Donawho
Institution: Abbott (United States)
Language: English

Topic: PARP inhibition in cancer therapy
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: veliparib, olaparib, PARP inhibitors, temozolomide, drug potentiation, pharmacodynamic biomarkers, B16F10 melanoma, plasma drug concentration, dosing regimen, DNA damage
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2183964012
FWCI: 4.051
Cites: 42
Cited by: 66
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms